Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06578195 · ClinicalTrials.gov registry record
ASSESS ALL ALS Study
A clinical trial of Amyotrophic Lateral Sclerosis, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 20
- Study locations
NCT06578195: Recruiting study of Amyotrophic Lateral Sclerosis, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
NCT06578195 is a study of Amyotrophic Lateral Sclerosis that is actively recruiting participants, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 2,000 participants, above the 878-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (128% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06578195, a study of Amyotrophic Lateral Sclerosis, is actively recruiting participants, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) and managed by two clinical coordinating centers (CCC) at Barrow Neurological Institute and Massachusetts General Hospital. The clinical sites are distributed across the country, and led by a group of collaborative principal investigators. Once data and samples are collected and harmonized, it will be made available to research community for future research into ALS and related neurological diseases. ASSESS protocol is specific for symptomatic ALS and control participants. This protocol includes both on-site and off-site(remote) participants. The participants will be followed for 24 months (2 years), and will include collection of medical history, clinical outcomes, and blood samples once in 4 months. Additionally, the participants will complete patient reported outcomes and speech recordings once a month. Participants who are coming into clinic may also provide optional Cerebrospinal Fluid (CSF) samples.
Primary Outcome
Questionnaire administered by a clinician that includes a series of questions about participants' ability to function in certain daily activities. Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Conditions Studied
Study Locations (20)
California
- University of California, Irvine - Irvine
- University of California San Diego - La Jolla
- University of California, San Francisco - San Francisco
Maryland
- John Hopkins University - Baltimore
- Nih/Ninds - Bethseda
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Health - Detroit
Alabama
- University of Alabama Birmingham - Birmingham
Arizona
- Barrow Neurological Institute - Phoenix
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Connecticut
- Hospital For Special Care - New Britain
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2029-07-25 |
What NCT06578195 shows while recruiting
NCT06578195 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 878-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (128% higher).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT06578195 names 20 study sites across 16 states, led by California, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT06578195 about?
NCT06578195 is a clinical study titled "ASSESS ALL ALS Study". The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Healt...
What is the current status of trial NCT06578195?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2024-07-25. Estimated completion is 2029-07-25.
What conditions does trial NCT06578195 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
Who is sponsoring clinical trial NCT06578195?
This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06578195 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06578195's enrollment target sits among peer trials
2,000 7th of 102 higher than 95 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
RECRUITING · NA
-
Assessing Perceptual Effects of Interactive Tasks
RECRUITING · NA
-
PREVENT ALL ALS Study
RECRUITING
-
Spinal Cord Associative Plasticity for ALS
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI